SJS Investment Consulting’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

SJS Investment Consulting’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2	Closed	-$204	–	1658
2023 Q2	$204	Buy	+2	New	+$189	﹤0.01%	1403

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

SJS Investment Consulting's RETA Position: Q3 2023 in Review

SJS Investment Consulting sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 2 shares — an estimated $204 sold.

SJS Investment Consulting first reported a position in RETA in Q2 2023 and held it in 1 quarter. The position peaked at $204 in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

SJS Investment Consulting reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
SJS Investment Consulting sold 2 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $204.
SJS Investment Consulting first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2023 and held it in 1 quarter.
SJS Investment Consulting's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $204 in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on SJS Investment Consulting's 13F filing for Q3 2023, filed 17 Oct 2023.